SYDNEY, Dec 13 (Reuters) - Australian biopharmaceutical giant CSL Ltd confirmed on Monday it is in talks to buy Swiss drugmaker Vifor Pharma Ltd in a deal reported by media to be worth about A$10 billion ($7.2 billion), anyerwisata.com as it looks to diversify beyond blood plasma products.
The talks, which were first reported earlier this month, come as Australia's fourth-largest company faces pressure to generate growth outside its main businesses of collecting blood plasma to make treatments for usora.org rare diseases and vaccine production.
CSL has pointed to a soft market for http://snapchat-emoji.com/ blood collections due to COVID-19 movement restrictions and concerns about the coronavirus, lab-townhouse.com although it has said collection rates are improving for http://disinfo2018.com the business unit which generates nearly nine-tenths of its profit.
Prospects for CSL's vaccine business, karmania.net meanwhile, dimmed after it suspended its own COVID-19 vaccine development and Australia opted for Pfizer/BioNTech's product as its major inoculation tool over AstraZeneca Plc's shot, http://Sketching07.com which CSL manufactures.
CSL, which declined to comment on media reports earlier this month about a possible buyout of Vifor, issued a brief statement saying the company "confirms that it is in discussions with Vifor Pharma Ltd regarding a potential transaction".
The statement gave no further detail and brtg.org added that there was no certainty any deal would eventuate.
However, they expressed concern that the benefits to CSL may be limited since there were no obvious major One-TwentyOne.com cost-savings from joining the companies.
"Should CSL be able to pick it up cheaply, potentially using equity, we can see the merits," said Damien Klassen, OnlineComCast.com head of investments at Nucleus Wealth, website which holds CSL shares.
"However, given Vifor's issues, the price paid will be very important," he added.
Shares of Vifor http://acmiindia.org surged over 20% when news of the potential deal was first reported.
Based on Friday's closing price, the company had a market value of 7.68 billion Swiss francs ($8.34 billion).
CSL shares closed slightly lower on Monday, against a higher overall Australia market.
($1 = 0.9213 Swiss francs) (Reporting by Byron Kaye in Sydney and Shashwat Awasthi and Sameer Manekar in Bengaluru; Editing by Subhranshu Sahu and website Richard Pullin)
Australia's CSL confirms buyout interest in Swiss drugmaker Vifor
por Christi Elliston (22/12/2021)
By Byron Kaye
SYDNEY, Dec 13 (Reuters) - Australian biopharmaceutical giant CSL Ltd confirmed on Monday it is in talks to buy Swiss drugmaker Vifor Pharma Ltd in a deal reported by media to be worth about A$10 billion ($7.2 billion), anyerwisata.com as it looks to diversify beyond blood plasma products.
The talks, which were first reported earlier this month, come as Australia's fourth-largest company faces pressure to generate growth outside its main businesses of collecting blood plasma to make treatments for usora.org rare diseases and vaccine production.
CSL has pointed to a soft market for http://snapchat-emoji.com/ blood collections due to COVID-19 movement restrictions and concerns about the coronavirus, lab-townhouse.com although it has said collection rates are improving for http://disinfo2018.com the business unit which generates nearly nine-tenths of its profit.
Prospects for CSL's vaccine business, karmania.net meanwhile, dimmed after it suspended its own COVID-19 vaccine development and Australia opted for Pfizer/BioNTech's product as its major inoculation tool over AstraZeneca Plc's shot, http://Sketching07.com which CSL manufactures.
CSL, which declined to comment on media reports earlier this month about a possible buyout of Vifor, issued a brief statement saying the company "confirms that it is in discussions with Vifor Pharma Ltd regarding a potential transaction".
The statement gave no further detail and brtg.org added that there was no certainty any deal would eventuate.
A successful deal would be CSL's biggest acquisition and thedalyblog.org give it access to Vifor's treatments for iron deficiency, kidney and http://mundogifs.com/ cardio-renal diseases, http://HouseOfObjects.org/ as well as its production sites in Switzerland http://Cambridge-Whos-Who.com/ and Portugal, http://ThePhotoSexpert.com analysts said.
However, they expressed concern that the benefits to CSL may be limited since there were no obvious major One-TwentyOne.com cost-savings from joining the companies.
Plus, GurgaonShoppingMalls.com they added, Vifor had a record of volatile earnings.
"Should CSL be able to pick it up cheaply, potentially using equity, we can see the merits," said Damien Klassen, OnlineComCast.com head of investments at Nucleus Wealth, website which holds CSL shares.
"However, given Vifor's issues, the price paid will be very important," he added.
Shares of Vifor http://acmiindia.org surged over 20% when news of the potential deal was first reported.
Based on Friday's closing price, the company had a market value of 7.68 billion Swiss francs ($8.34 billion).
CSL shares closed slightly lower on Monday, against a higher overall Australia market.
($1 = 0.9213 Swiss francs) (Reporting by Byron Kaye in Sydney and Shashwat Awasthi and Sameer Manekar in Bengaluru; Editing by Subhranshu Sahu and website Richard Pullin)